الفهرس 
ACKNOWLEDGEMENOnly 14 pages are availabe for public view
 |  | from | 319 |  |  |
| | | from | 319 | | |
Abstract
Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia resulting from relative or absolute insulin deficiency with or without insulin resistance. As anxiolytics may have influence on glycemic control in diabetics, the present study was conducted to investigate the possible influence of diazepam and buspirone in streptozotocin-induced DM and their possible interactions with rosiglitazone or glimepiride. Diabetes was induced by streptozotpcin (50 mg/kg i.p.). Rats were classified into 10 groups namely: normal control, diabetic control, rosiglitazone (10 mg/kg p.o.), glimepiride (10 mg/kg), diazepam (5 mg/kg) buspirone (20 mg/kg i.p.) or combination of diazepam or buspirone with rosiglitazone or glimepiride. All test drugs were given as single as well as repeated dose for one and two weeks. Diazepam significantly improved the effect of rosiglitazone or glimepiride on the levels of serum glucose, insulin, C-peptide, liver glycogen content and on oxidative stress biomarkers including serum lipid peroxides, blood glutathione levels and blood superoxide dismutase activity of diabetic rats. In conclusion, diazepam increased the antidiabetic and the antioxidant actions of rosiglitazone or glimepiride which may be of considerable value in the treatment of diabetes mellitus. There was no significant interaction between rosiglitazone or glimepiride and buspirone on the measured parameters, so, buspirone can be safely administered as an anxiolytic in diabetic patients treated with rosiglitazone.